Colorado Prevention Center
- Address
- 2115 Scranton Street Suite 2040
Sponsor Overview
Specializations
Heart Failure
The Colorado Prevention Center focuses on heart failure across a range of clinical settings, including patients who are intolerant of or not eligible for steroidal mineralocorticoid receptor antagonists, as well as those hospitalized with worsening cardiac disease.
- HFrEF
- HFmrEF
- HFpEF
Its research activity includes both chronic and acute presentations of heart failure, with attention to clinical outcomes and symptom burden in hospitalized populations.
Cardiovascular Pharmacotherapy
Clinical studies supported by the sponsor examine finerenone in cardiovascular care, with interest in its role for patients with heart failure who have limited treatment options.
- Non-steroidal mineralocorticoid receptor antagonism
- SGLT2 inhibitors
- Combination therapy
The sponsor’s therapeutic focus includes medication strategies used alongside usual care in both outpatient and inpatient cardiology settings.
Acute Cardiac Care
Research activity also centers on hospitalized heart failure, including patients with acute decompensated heart failure and those requiring early treatment decisions during admission.
- Inpatient heart failure management
- Acute decompensation
- Clinical outcome assessment
This area reflects interest in treatment approaches that address short-term events and longer-term cardiovascular risk after hospitalization.
Patient-Reported Outcomes
The sponsor’s trials incorporate health status and symptom-focused measures in heart failure, including assessment of daily symptom burden and functional impact.
- Kansas City Cardiomyopathy Questionnaire
- Symptom burden
- Quality of life
These outcomes align with the sponsor’s interest in both survival-related endpoints and the lived experience of patients with cardiac disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Finerenone in Reducing Morbidity and Mortality in Heart Failure Patients with LVEF ≥40% Hospitalized for Acute Decompensated Heart Failure |  Austria Bulgaria Croatia Czechia Germany Greece Hungary Italy Latvia Lithuania Poland Portugal Romania Slovakia Spain | Recruiting |
| Evaluation of Finerenone Efficacy and Safety in Heart Failure Patients with Reduced Ejection Fraction Intolerant or Ineligible for Steroidal Mineralocorticoid Receptor Antagonists | Croatia Czechia Greece Hungary Italy Poland Spain | Recruiting |
| Evaluation of the Efficacy and Safety of Finerenone and Empagliflozin Combination Therapy in Hospitalized Heart Failure Patients | Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 178 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases3 trials359 other sponsors
Partnered Research Centres
178 centres- Address
- Ringstraße 60, 5280 Braunau am Inn
- Address
- Vassilissis Sofias Avenue 80, 115 28 Athens
- Address
- Ligonines G 12, Alytaus M Sav, 62114 Alytus
- Address
- 28 ‘Tsar Assen’ Str, Triaditsa district, 1000 Sofia
- Address
- Ul. Franklina Delano Roosevelta 2, 47-200 Kedzierzyn-Kozle
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Colorado Prevention Center.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.